V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210001833 | 210010903 | 1.61 | 67.7 | Adjuvant (A) | 2018-05-19 | 2018-07-28 | ABEMACICLIB + FULVESTRANT | null | N | EC | 101799390 |
| 210001844 | 210010904 | 1.81 | 75 | Neo-adjuvant (N) | 2020-10-03 | 2020-12-30 | Everolimus 10mg | N | N | FULVESTRANT + PALBOCICLIB | 100737108 |
| 210001876 | 210010905 | 1.55 | 69.7 | Palliative (P) | 2018-07-21 | 2018-11-01 | null | N | N | PACLITAXEL + PERTUZUMAB + TRASTUZUMAB | 100936518 |
| 210001963 | 210010909 | 1.64 | 96.7 | Palliative (P) | 2020-02-04 | 2020-02-09 | ABEMACICLIB + FULVESTRANT | 02 | N | TRIAL UNSPECIFIED | 101232145 |
| 210001994 | 210010910 | 1.58 | 69.7 | null | 2019-09-11 | 2019-12-16 | Palbociclib | 02 | null | CYCLOPHOSPHAMIDE + DOCETAXEL | 100155303 |
| 210002016 | 210010911 | 1.65 | 58.4 | null | 2018-07-13 | 2018-09-15 | Epirubicin (weekly) | null | null | EC | 101019512 |
| 210002091 | 210010914 | 1.76 | 75.95 | null | null | 2021-10-15 | EC | null | null | EC | 101005329 |
| 210002144 | 210010917 | 1.54 | 76 | Adjuvant (A) | 2019-03-02 | 2019-03-03 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | null | N | CYCLOPHOSPHAMIDE + DOCETAXEL | 100163344 |
| 210002167 | 210010918 | 1.58 | 67 | Neo-adjuvant (N) | 2018-09-17 | 2018-09-17 | PERTUZUMAB + TRASTUZUMAB | 02 | N | PERTUZUMAB + TRASTUZUMAB | 100450806 |
| 210002229 | 210010919 | 1.65 | 88.3 | Palliative (P) | 2020-01-18 | 2020-01-25 | VINORELBINE | 02 | N | VINORELBINE | 101584469 |
| 210002412 | 210010924 | 1.69 | 64 | Adjuvant (A) | 2018-07-10 | 2018-07-24 | EC | 02 | N | EC | 100071313 |
| 210002431 | 210010925 | 1.68 | 73.9 | Adjuvant (A) | 2020-04-03 | 2020-10-10 | Pertuzumab + Trastuzumab IV | 02 | null | PERTUZUMAB + TRASTUZUMAB | 100024558 |
| 210002443 | 210010927 | 1.55 | 55.1 | Adjuvant (A) | null | 2018-06-12 | Capecitabine | null | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101261577 |
| 210002467 | 210010928 | 1.62 | 54.4 | Palliative (P) | 2021-04-15 | 2021-05-06 | Carboplatin AUC 2 - 5 | null | N | CARBOPLATIN | 100194392 |
| 210002501 | 210010929 | 1.58 | 63.1 | null | null | 2018-12-12 | null | null | null | PACLITAXEL + TRASTUZUMAB | 100816955 |
| 210002628 | 210010930 | 1.69 | 81.8 | Neo-adjuvant (N) | 2017-10-21 | 2018-09-05 | PERTUZUMAB + TRASTUZUMAB | 02 | N | PERTUZUMAB + TRASTUZUMAB | 101416903 |
| 210002637 | 210010931 | 1.57 | 65.4 | Neo-adjuvant (N) | 2016-12-02 | 2020-02-10 | Letrozole + Palbociclib | 01 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101493616 |
| 210002751 | 210010932 | null | 122.6 | null | null | 2018-03-25 | PERTUZUMAB + TRASTUZUMAB | 02 | null | PERTUZUMAB + TRASTUZUMAB | 100755182 |
| 210002805 | 210010933 | null | 68.3 | null | 2016-11-23 | 2017-03-15 | PERTUZUMAB + TRASTUZUMAB | 02 | null | PERTUZUMAB + TRASTUZUMAB | 101615942 |
| 210002826 | 210010934 | 1.61 | 75 | Neo-adjuvant (N) | 2020-05-18 | 2020-05-25 | null | null | N | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 100004928 |
| 210002947 | 210010937 | 1.63 | 61.3 | Neo-adjuvant (N) | 2019-05-24 | 2019-06-03 | Capecitabine | 02 | N | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 101147575 |
| 210003252 | 210010940 | 1.7 | 81.7 | null | 2021-04-05 | 2021-11-30 | CARBOPLATIN + DOCETAXEL + Pertuzumab + Trastuzumab | 02 | null | ATEZOLIZUMAB + NAB-PACLITAXEL | 101129757 |
| 210003324 | 210010941 | 1.73 | 91.2 | Adjuvant (A) | 2022-01-14 | 2022-01-29 | FEC 100 | null | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100837867 |
| 210003439 | 210010943 | 1.6 | 77.9 | Adjuvant (A) | 2017-08-28 | 2017-11-05 | ABEMACICLIB + FULVESTRANT | 02 | N | ROSCO TRIAL | 100457558 |
| 210003476 | 210010946 | 1.62 | 84.4 | null | 2020-02-12 | 2020-03-05 | null | null | null | ATEZOLIZUMAB + NAB-PACLITAXEL | 100010778 |
| 210003632 | 210010949 | 1.6 | 74.4 | Adjuvant (A) | 2018-12-31 | 2019-01-08 | null | null | N | CYCLOPHOSPHAMIDE + DOXORUBICIN | 100630244 |
| 210003725 | 210010951 | null | null | null | null | 2018-09-21 | PERTUZUMAB + TRASTUZUMAB | 02 | null | PERTUZUMAB + TRASTUZUMAB | 100388097 |
| 210003779 | 210010952 | 1.66 | null | null | 2017-08-12 | 2017-11-05 | TCH (21 day Trastuzumab) Maint | null | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101717009 |
| 210003842 | 210010954 | null | 71.6 | Palliative (P) | 2020-12-24 | 2020-12-27 | FEC | 02 | N | FEC | 101238416 |
| 210003568 | 210010958 | 1.67 | 65.1 | null | 2019-06-03 | 2019-06-11 | Letrozole + Palbociclib | null | null | EC | 100026134 |
| 210002753 | 210011337 | 1.65 | 65 | Neo-adjuvant (N) | 2021-10-21 | 2022-02-19 | EC | null | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 101849442 |
| 210002754 | 210011338 | 1.63 | 61.5 | Adjuvant (A) | 2019-10-20 | 2019-10-20 | Paclitaxel 80mg/m2 day 1 8 15 | null | N | PACLITAXEL | 101343732 |
| 210002756 | 210011339 | null | 106.1 | null | null | 2020-07-25 | Paclitaxel 7 day | 02 | null | PACLITAXEL | 100142963 |
| 210002757 | 210011340 | null | 94.1 | null | null | 2020-06-23 | Docetaxel | 02 | null | DOCETAXEL | 101755554 |
| 210002760 | 210011342 | null | 95 | null | null | 2020-06-26 | Trastuzumab Subcutaneous | null | null | TRASTUZUMAB | 101454782 |
| 210002761 | 210011343 | 1.71 | 75.5 | Adjuvant (A) | null | 2019-06-15 | Trastuzumab | null | N | TRASTUZUMAB | 100837925 |
| 210002764 | 210011344 | 1.63 | 100.6 | Adjuvant (A) | null | 2020-04-08 | TRASTUZUMAB | 02 | N | TRASTUZUMAB | 100270661 |
| 210002767 | 210011345 | null | null | null | 2019-04-27 | 2020-05-29 | Docetaxel 100mg/m2 (21 day) | 02 | null | DOCETAXEL | 101856601 |
| 210002768 | 210011346 | 1.65 | 92.8 | Adjuvant (A) | 2017-02-19 | 2017-05-17 | Trastuzumab Subcutaneous | 02 | N | TRASTUZUMAB | 100461865 |
| 210002773 | 210011347 | 1.54 | 85.8 | Neo-adjuvant (N) | null | 2017-09-21 | EC | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN | 100097853 |
| 210002774 | 210011348 | 1.64 | 106.4 | Adjuvant (A) | null | 2022-03-10 | Docetaxel 100mg/m2 (21 day) | 02 | N | DOCETAXEL | 100800687 |
| 210002777 | 210011349 | 1.55 | 45.2 | Adjuvant (A) | 2018-09-14 | 2020-07-10 | TRASTUZUMAB | 02 | N | TRASTUZUMAB | 100476756 |
| 210002779 | 210011350 | 1.6 | 58.1 | Adjuvant (A) | null | 2021-11-22 | Paclitaxel 80mg/m2 day 1 8 15 | null | N | PACLITAXEL | 100559144 |
| 210002783 | 210011353 | 1.51 | 80.1 | Palliative (P) | null | 2022-01-13 | Docetaxel 100mg/m2 (21 day) | 02 | N | DOCETAXEL | 101475663 |
| 210002786 | 210011354 | 1.63 | 70 | Neo-adjuvant (N) | 2020-01-30 | 2020-03-02 | Trastuzumab Subcutaneous | 02 | N | TRASTUZUMAB | 100132969 |
| 210002787 | 210011355 | null | 87 | null | null | 2022-02-08 | Paclitaxel 7 day | 02 | null | PACLITAXEL | 100511243 |
| 210002791 | 210011356 | 1.56 | 104.9 | Neo-adjuvant (N) | 2019-12-17 | 2020-02-25 | TRASTUZUMAB | 02 | N | TRASTUZUMAB | 100848575 |
| 210002793 | 210011357 | 1.6 | 93.8 | Adjuvant (A) | 2019-03-11 | 2019-04-23 | Docetaxel 75mg/m2 (21 day) | 02 | N | DOCETAXEL | 101057989 |
| 210002794 | 210011358 | 1.65 | null | Palliative (P) | 2021-12-24 | 2022-05-17 | Trastuzumab Subcutaneous | null | N | TRASTUZUMAB | 100726234 |
| 210002797 | 210011359 | 1.67 | 93.4 | Adjuvant (A) | 2018-06-24 | 2018-09-24 | Docetaxel | null | N | DOCETAXEL | 100731070 |